References
Key articles
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edition, text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.
Clinical Guideline Committee (CGC) Members, ASAM Team, AAAP Team, et al. The ASAM/AAAP clinical practice guideline on the management of stimulant use disorder. J Addict Med. 2024 May-Jun 01;18(1s suppl 1):1-56.Full text Abstract
Department of Health and Social Care. Drug misuse and dependence: UK guidelines on clinical management. Dec 2017 [internet publication].Full text
World Health Organization. Guidelines for identification and management of substance use and substance use disorders in pregnancy. Nov 2014 [internet publication].Full text
Reference articles
1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edition, text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.
2. World Health Organization. International statistical classification of diseases and related health problems (ICD). May 2024 [internet publication].Full text
3. Chang A, Osterloh J, Thomas J. Levamisole: a dangerous new cocaine adulterant. Clin Pharmacol Ther. 2010 Sep;88(3):408-11. Abstract
4. Bradford M, Rosenberg B, Moreno J, et al. Bilateral necrosis of earlobes and cheeks: another complication of cocaine contaminated with levamisole. Ann Intern Med. 2010 Jun 1;152(11):758-9. Abstract
5. United Nations Office on Drugs and Crime. World drug report 2021. Drug market trends: cocaine amphetamine-type stimulants. Jun 2021 [internet publication].Full text
6. GBD 2016 Alcohol and Drug Use Collaborators. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry. 2018 Dec;5(12):987-1012.Full text Abstract
7. Substance Abuse and Mental Health Services Administration. Results from the 2013 National Survey on Drug Use and Health: summary of national findings. Sep 2014 [internet publication].Full text
8. Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2023 National Survey on Drug Use and Health. Jul 2024 [internet publication].Full text
9. GOV.UK. Office for Health Improvement and Disparities. Adult substance misuse treatment statistics 2020 to 2021: report. Nov 2021 [internet publication].Full text
10. European Monitoring Centre for Drugs and Drug Addiction. European drug report 2021: trends and developments. Jun 2021 [internet publication].Full text
11. Haasen C, Prinzleve M, Zurhold H, et al. Cocaine use in Europe - a multi-centre study. Methodology and prevalence estimates. Eur Addict Res. 2004;10(4):139-46. Abstract
12. Kranzler HR, Wilcox M, Weiss RD, et al. The validity of cocaine dependence subtypes. Addict Behav. 2008 Jan;33(1):41-53. Abstract
13. Bühler KM, Giné E, Echeverry-Alzate V, et al. Common single nucleotide variants underlying drug addiction: more than a decade of research. Addict Biol. 2015 Sep;20(5):845-71. Abstract
14. Gorwood P, Le Strat Y, Ramoz N, et al. Genetics of dopamine receptors and drug addiction. Hum Genet. 2012 Jun;131(6):803-22. Abstract
15. Jensen KP. A review of genome-wide association studies of stimulant and opioid use disorders. Mol Neuropsychiatry. 2016 May;2(1):37-45.Full text Abstract
16. Huggett SB, Stallings MC. Cocaine'omics: genome-wide and transcriptome-wide analyses provide biological insight into cocaine use and dependence. Addict Biol. 2020 Mar;25(2):e12719. Abstract
17. Henning RJ, Cuevas J. Cocaine activates calcium/calmodulin kinase II and causes cardiomyocyte hypertrophy. J Cardiovasc Pharmacol. 2006 Jul;48(1):802-13. Abstract
18. Karch SB, Green GS, Young S. Myocardial hypertrophy and coronary artery disease in male cocaine users. J Forensic Sci. 1995 Jul;40(4):591-5. Abstract
19. Haider AW, Larson MG, Benjamin EJ, et al. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol. 1998 Nov;32(5):1454-9.Full text Abstract
20. Graf J, Lynch K, Yeh CL, et al. Purpura, cutaneous necrosis, and antineutrophil cytoplasmic antibodies associated with levamisole-adulterated cocaine. Arthritis Rheum. 2011 Dec;63(12):3998-4001.Full text Abstract
21. Whitesell M, Bachand A, Peel J, et al. Familial, social, and individual factors contributing to risk for adolescent substance use. J Addict. 2013;2013:579310.Full text Abstract
22. Kilpatrick DG, Acierno R, Saunders B, et al. Risk factors for adolescent substance abuse and dependence: data from a national sample. J Consult Clin Psychol. 2000 Feb;68(1):19-30. Abstract
23. Hawkins JD, Catalano RF, Miller JY. Risk and protective factors for alcohol and other drug problems in adolescence and early adulthood: implications for substance abuse prevention. Psychol Bull. 1992 Jul;112(1):64-105. Abstract
24. Stiltner B, Pietrzak RH, Tylee DS, et al. Polysubstance addiction patterns among 7,989 individuals with cocaine use disorder. iScience. 2023 Aug 18;26(8):107336.Full text Abstract
25. Swendsen J, Conway KP, Degenhardt L, et al. Mental disorders as risk factors for substance use, abuse and dependence: results from the 10-year follow-up of the National Comorbidity Survey. Addiction. 2010 Jun;105(6):1117-28.Full text Abstract
26. US Preventive Services Task Force, Krist AH, Davidson KW, et al. Primary care-based interventions to prevent illicit drug use in children, adolescents, and young adults: US Preventive Services Task Force recommendation statement. JAMA. 2020 May 26;323(20):2060-6.Full text Abstract
27. Clinical Guideline Committee (CGC) Members, ASAM Team, AAAP Team, et al. The ASAM/AAAP clinical practice guideline on the management of stimulant use disorder. J Addict Med. 2024 May-Jun 01;18(1s suppl 1):1-56.Full text Abstract
28. Faruque S, Edlin BR, McCoy CB, et al. Crack cocaine smoking and oral sores in three inner-city neighborhoods. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Sep;13(1):87-92. Abstract
29. Gatof D, Albert RK. Bilateral thumb burns leading to the diagnosis of crack lung. Chest. 2002 Jan;121(1):289-91. Abstract
30. Harris M, Scott J, Wright T, et al. Injecting-related health harms and overuse of acidifiers among people who inject heroin and crack cocaine in London: a mixed-methods study. Harm Reduct J. 2019 Nov 13;16(1):60.Full text Abstract
31. Chaiben CL, Macedo NF, Batista TBD, et al. Salivary protein candidates for biomarkers of oral disorders in people with a crack cocaine use disorder. J Appl Oral Sci. 2023 May 15:31:e20220480.Full text Abstract
32. Melo CAA, Guimarães HRG, Medeiros RCF, et al. Oral changes in cocaine abusers: an integrative review. Braz J Otorhinolaryngol. 2022 Jul-Aug;88(4):633-41.Full text Abstract
33. Wiens MO, Son WK, Ross C, et al. Cases: Cocaine adulterant linked to neutropenia. CMAJ. 2010 Jan 12;182(1):57-9.Full text Abstract
34. Department of Health and Social Care. Drug misuse and dependence: UK guidelines on clinical management. Dec 2017 [internet publication].Full text
35. Anderson JL, Adams CD, Antman EM, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013 Jun 11;127(23):e663-828.Full text Abstract
36. Moçambique M, Hoffmann A, Roglio VS, et al. Prevalence of suicide in cocaine users accessing health services: a systematic review and meta-analysis. Braz J Psychiatry. 2022 Jun 24;44(4):441-8.Full text Abstract
37. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.Full text Abstract
38. Robertson KE, Martin TN, Rae AP. Brugada-pattern ECG and cardiac arrest in cocaine toxicity: reading between the white lines. Heart. 2010 Apr;96(8):643-4. Abstract
39. Karch SB, Stephens BG, Ho CH. Methamphetamine-related deaths in San Francisco: demographic, pathologic, and toxicologic profiles. J Forensic Sci. 1999 Mar;44(2):359-68. Abstract
40. Spitzer RL, Williams JB, Kroenke K, et al. Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 study. JAMA. 1994 Dec 14;272(22):1749-56. Abstract
41. Hirschfeld RM, Williams JB, Spitzer RL, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry. 2000 Nov;157(11):1873-5.Full text Abstract
42. Namera A, Kawamura M, Nakamoto A, et al. Comprehensive review of the detection methods for synthetic cannabinoids and cathinones. Forensic Toxicol. 2015;33(2):175-94.Full text Abstract
43. Mash DC, Duque L, Pablo J, et al. Brain biomarkers for identifying excited delirium as a cause of sudden death. Forensic Sci Int. 2009 Sep 10;190(1-3):e13-9. Abstract
44. Karch SB. Cathinone neurotoxicity ("The "3Ms"). Curr Neuropharmacol. 2015 Jan;13(1):21-5.Full text Abstract
45. US Preventive Services Task Force. Final recommendation statement. Unhealthy drug use: screening. Jun 2020 [internet publication].Full text
46. American College of Surgeons. Best practices guidelines: screening and intervention for mental health disorders and substance use and misuse in the acute trauma patient. Dec 2022 [internet publication].Full text
47. World Health Organization. Guidelines for identification and management of substance use and substance use disorders in pregnancy. Nov 2014 [internet publication].Full text
48. National Institute for Health and Care Excellence. Postnatal care. Apr 2021 [internet publication].Full text
49. National Institute for Health and Care Excellence. Coexisting severe mental illness (psychosis) and substance misuse: assessment and management in healthcare settings. Mar 2011 [internet publication].Full text
50. Minozzi S, Saulle R, Amato L, et al. Psychosocial interventions for stimulant use disorder. Cochrane Database Syst Rev. 2024 Feb 15;2(2):CD011866. Abstract
51. Minozzi S, Amato L, Pani PP, et al. Dopamine agonists for the treatment of cocaine dependence. Cochrane Database Syst Rev. 2015 May 27;(5):CD003352.Full text Abstract
52. Indave BI, Minozzi S, Pani PP, et al. Antipsychotic medications for cocaine dependence. Cochrane Database Syst Rev. 2016 Mar 19;(3):CD006306.Full text Abstract
53. Castells X, Cunill R, Pérez-Mañá C, et al. Psychostimulant drugs for cocaine dependence. Cochrane Database Syst Rev. 2016 Sep 27;9(9):CD007380.Full text Abstract
54. Crits-Christoph P, Siqueland L, Blaine J, et al. Psychosocial treatments for cocaine dependence: National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Arch Gen Psychiatry. 1999 Jun;56(6):493-502.Full text Abstract
55. McLellan AT, Hagan TA, Meyers K, et al. "Intensive" outpatient substance abuse treatment: comparisons with "traditional" outpatient treatment. J Addict Dis. 1997;16(2):57-84. Abstract
56. National Institute for Health and Care Excellence. Drug misuse in over 16s: psychosocial interventions. Jul 2007 [internet publication].Full text
57. Carroll KM, Onken LS. Behavioral therapies for drug abuse. Am J Psychiatry. 2005 Aug;162(8):1452-60.Full text Abstract
58. McGovern R, Newham JJ, Addison MT, et al. Effectiveness of psychosocial interventions for reducing parental substance misuse. Cochrane Database Syst Rev. 2021 Mar 16;(3):CD012823.Full text Abstract
59. Banbery, J. Treatment of withdrawal syndromes. In: Karch SB, ed. Drug abuse handbook. 2nd ed. Boca Raton: CRC Press; 2006.
60. McCarty D, Braude L, Lyman DR, et al. Substance abuse intensive outpatient programs: assessing the evidence. Psychiatr Serv. 2014 Jun 1;65(6):718-26.Full text Abstract
61. Kampman KM. The treatment of cocaine use disorder. Sci Adv. 2019 Oct;5(10):eaax1532.Full text Abstract
62. Coviello DM, Alterman AI, Rutherford MJ, et al. The effectiveness of two intensities of psychosocial treatment for cocaine dependence. Drug Alcohol Depend. 2001 Jan 1;61(2):145-54. Abstract
63. Bentzley BS, Han SS, Neuner S, et al. Comparison of treatments for cocaine use disorder among adults: a systematic review and meta-analysis. JAMA Netw Open. 2021 May 3;4(5):e218049.Full text Abstract
64. Carroll KM, Rounsaville BJ, Nich C, et al. One-year follow-up of psychotherapy and pharmacotherapy for cocaine dependence. Delayed emergence of psychotherapy effects. Arch Gen Psychiatry. 1994 Dec;51(12):989-97. Abstract
65. Carroll KM, Nich C, Ball SA, et al. One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: sustained effects of treatment. Addiction. 2000 Sep;95(9):1335-49. Abstract
66. Maude-Griffin PM, Hohenstein JM, Humfleet GL, et al. Superior efficacy of cognitive-behavioral therapy for urban crack cocaine abusers: main and matching effects. J Consult Clin Psychol. 1998 Oct;66(5):832-7. Abstract
67. Kiluk BD, Nich C, Buck MB, et al. Randomized clinical trial of computerized and clinician-delivered CBT in comparison with standard outpatient treatment for substance use disorders: primary within-treatment and follow-up outcomes. Am J Psychiatry. 2018 Sep 1;175(9):853-63.Full text Abstract
68. Smedslund G, Berg RC, Hammerstrøm KT, et al. Motivational interviewing for substance abuse. Cochrane Database Syst Rev. 2011 May 11;(5):CD008063.Full text Abstract
69. Chan B, Kondo K, Freeman M, et al. Pharmacotherapy for cocaine use disorder-a systematic review and meta-analysis. J Gen Intern Med. 2019 Dec;34(12):2858-73.Full text Abstract
70. Silverman K, Svikis D, Robles E, et al. A reinforcement-based therapeutic workplace for the treatment of drug abuse: six-month abstinence outcomes. Exp Clin Psychopharmacol. 2001 Feb;9(1):14-23. Abstract
71. McKay JR, Van Horn DH, Lynch KG, et al. Who benefits from extended continuing care for cocaine dependence? Addict Behav. 2014 Mar;39(3):660-8.Full text Abstract
72. Nourredine M, Jurek L, Angerville B, et al. Use of topiramate in the spectrum of addictive and eating disorders: a systematic review comparing treatment schemes, efficacy, and safety features. CNS Drugs. 2021 Feb;35(2):177-213. Abstract
73. Anderson AL, Reid MS, Li SH, et al. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend. 2009 Sep 1;104(1-2):133-9.Full text Abstract
74. Kampman KM, Lynch KG, Pettinati HM, et al. A double blind, placebo controlled trial of modafinil for the treatment of cocaine dependence without co-morbid alcohol dependence. Drug Alcohol Depend. 2015 Oct 1;155:105-10.Full text Abstract
75. Grabowski J, Rhoades H, Schmitz J, et al. Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J Clin Psychopharmacol. 2001 Oct;21(5):522-6. Abstract
76. Grabowski J, Rhoades H, Stotts A, et al. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology. 2004 May;29(5):969-81.Full text Abstract
77. Mooney ME, Herin DV, Schmitz JM, et al. Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2009 Apr 1;101(1-2):34-41.Full text Abstract
78. Tardelli VS, Bisaga A, Arcadepani FB, et al. Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis. Psychopharmacology (Berl). 2020 Aug;237(8):2233-55.Full text Abstract
79. Traccis F, Minozzi S, Trogu E, et al. Disulfiram for the treatment of cocaine dependence. Cochrane Database Syst Rev. 2024 Jan 5;1(1):CD007024. Abstract
80. Bloom BT, Bushell MJ. Vaccines against drug abuse-are we there yet? Vaccines (Basel). 2022 May 27;10(6):860.Full text Abstract
81. ClinicalTrials.gov. Safety study of a disrupted adenovirus (Ad) serotype cocaine vaccine for cocaine-dependent individuals. ClinicalTrials.gov Identifier: NCT02455479. Dec 2023 [internet publication].Full text
82. US Department of Veterans Affairs, Department of Defense. VA/DoD clinical practice guideline for the management of substance use disorders. 2021 [internet publication].Full text
83. Crowley R, Kirschner N, Dunn AS, et al. Health and public policy to facilitate effective prevention and treatment of substance use disorders involving illicit and prescription drugs: an American College of Physicians position paper. Ann Intern Med. 2017 May 16;166(10):733-6.Full text Abstract
84. National Institute for Health and Care Excellence. Drug misuse prevention: targeted interventions. Feb 2017 [internet publication].Full text
85. GOV.UK. Office for Health Improvement and Disparities. Adult substance misuse treatment statistics 2022 to 2023: report. Dec 2023 [internet publication].Full text
86. Palazón-Llecha A, Caparrós B, Trujols J, et al. Predictors of cocaine use disorder treatment outcomes: a systematic review. Syst Rev. 2024 May 8;13(1):124.Full text Abstract
87. Simpson DD, Joe GW, Broome KM. A national 5-year follow-up of treatment outcomes for cocaine dependence. Arch Gen Psychiatry. 2002 Jun;59(6):538-44.Full text Abstract
88. Peacock A, Tran LT, Larney S, et al. All-cause and cause-specific mortality among people with regular or problematic cocaine use: a systematic review and meta-analysis. Addiction. 2021 Apr;116(4):725-42.Full text Abstract
89. Mantinieks D, Schumann J, Drummer OH, et al. Stimulant use in suicides: a systematic review. Forensic Sci Int. 2022 Sep;338:111391. Abstract
90. Armoon B, SoleimanvandiAzar N, Fleury MJ, et al. Prevalence, sociodemographic variables, mental health condition, and type of drug use associated with suicide behaviors among people with substance use disorders: a systematic review and meta-analysis. J Addict Dis. 2021 Oct-Dec;39(4):550-69. Abstract
91. Howe AS, Boden BP. Heat-related illness in athletes. Am J Sports Med. 2007 Aug;35(8):1384-95. Abstract
92. Qureshi AI, Suri MF, Guterman LR, et al. Cocaine use and the likelihood of nonfatal myocardial infarction and stroke: data from the Third National Health and Nutrition Examination Survey. Circulation. 2001 Jan 30;103(4):502-6.Full text Abstract
93. McCord J, Jneid H, Hollander JE, et al. Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. Circulation. 2008 Apr 8;117(14):1897-907.Full text Abstract
94. Karch SB. Cocaine cardiovascular toxicity. South Med J. 2005 Aug;98(8):794-9. Abstract
95. Bauman JL, DiDomenico RJ. Cocaine-induced channelopathies: emerging evidence on the multiple mechanisms of sudden death. J Cardiovasc Pharmacol Ther. 2002 Jul;7(3):195-202. Abstract
96. Howington JU, Kutz SC, Wilding GE, et al. Cocaine use as a predictor of outcome in aneurysmal subarachnoid hemorrhage. J Neurosurg. 2003 Aug;99(2):271-5. Abstract
97. Bartzokis G, Beckson M, Wirshing DA, et al. Choreoathetoid movements in cocaine dependence. Biol Psychiatry. 1999 Jun 15;45(12):1630-5. Abstract
98. Sabe M, Zhao N, Kaiser S. A systematic review and meta-analysis of the prevalence of cocaine-induced psychosis in cocaine users. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jul 13;109:110263.Full text
99. Goel N, Pullman JM, Coco M. Cocaine and kidney injury: a kaleidoscope of pathology. Clin Kidney J. 2014 Dec;7(6):513-7.Full text Abstract
100. Forrester JM, Steele AW, Waldron JA, et al. Crack lung: an acute pulmonary syndrome with a spectrum of clinical and histopathologic findings. Am Rev Respir Dis. 1990 Aug;142(2):462-7. Abstract
101. Barsky SH, Roth MD, Kleerup EC, et al. Histopathologic and molecular alterations in bronchial epithelium in habitual smokers of marijuana, cocaine, and/or tobacco. J Natl Cancer Inst. 1998 Aug 19;90(16):1198-205.Full text Abstract
102. Bertol E, Mari F, Milia MG, et al. Determination of aminorex in human urine samples by GC-MS after use of levamisole. J Pharm Biomed Anal. 2011 Jul 15;55(5):1186-9. Abstract
103. Karch SB, Mari F, Bartolini V, et al. Aminorex poisoning in cocaine abusers. Int J Cardiol. 2012 Jul 26;158(3):344-6. Abstract
104. Murphy EL, DeVita D, Liu H, et al. Risk factors for skin and soft-tissue abscesses among injection drug users: a case-control study. Clin Infect Dis. 2001 Jul 1;33(1):35-40.Full text Abstract
105. Jacobson JM, Hirschman SZ. Necrotizing fasciitis complicating intravenous drug abuse. Arch Intern Med. 1982 Mar;142(3):634-5. Abstract
106. Antoniazzi RP, Sari AR, Casarin M, et al. Association between crack cocaine use and reduced salivary flow. Braz Oral Res. 2017 Jun 5;31:e42.Full text Abstract
107. Fung EY, Giannini PJ. Implications of drug dependence on dental patient management. Gen Dent. 2010 May-Jun;58(3):236-41; quiz 242-3. Abstract
108. Gourgoutis G, Das G. Gastrointestinal manifestations of cocaine addiction. Int J Clin Pharmacol Ther. 1994 Mar;32(3):136-41. Abstract
109. Fox CH. Cocaine use in pregnancy. J Am Board Fam Pract. 1994 May-Jun;7(3):225-8. Abstract
110. Dos Santos JF, de Melo Bastos Cavalcante C, Barbosa FT, et al. Maternal, fetal and neonatal consequences associated with the use of crack cocaine during the gestational period: a systematic review and meta-analysis. Arch Gynecol Obstet. 2018 Sep;298(3):487-503. Abstract
Use of this content is subject to our disclaimer